Skip to main content

Advertisement

Figure 3 | Molecular Cancer

Figure 3

From: Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1

Figure 3

IL-2 and INF-γ levels in mouse serum and expression of GPF, GM-SCF, IL-21 and Rae-1 in liver cancer tissue in each treatment group. Effect of the plasmids on IL-2 and INF-γ levels in mouse serum of each group that included: control, pGFP-IRES, pGM-CSF-IRES, pIL21-IRES, pGM-CSF-IRES-IL21, and pGM-CSF-GFP-IRES-Rae-1-IL-21. At 10d after treatment, mouse serum was quantified by ELISA for IL-2 levels and INF-γ levels. Tumor tissue was assessed by RT-PCR and Western blot to determine GPF, GM-SCF, IL-21 and Rae-1 expression. A: IL-2 levels were detected and expressed as mean ± standard deviation (n = 3); B: INF-γ levels were tested by ELISA and expressed as mean ± standard deviation (n = 3); C: RT-PCR analysis of GPF, GM-SCF, IL-21 and Rae-1 in liver cancer tissue (n = 3). D: Western blot analysis of GPF, GM-SCF, IL-21 and Rae-1 in liver cancer tissue (n = 3). D: Western blot analysis of GPF, GM-SCF, IL-21 and Rae-1 in liver cancer tissue (n = 3). E: relative values of Rae-1 protein or mRNA expression in liver cancer tissue of each group, expressed as mean ± standard deviation (n = 3). Note: Lane 1, control. Lane 2, pIRES/GFP. Lane 3, pIRES/IL2. Lane 4, pIRES/GM-SCF. Lane 5, pIRES/GM-SCF-IL21. Lane 6, pIRES/combination. * P < 0.05 and ** P < 0.01, as compared with control. # P < 0.05 and ## P < 0.01, as compared with IRES/GM-SCF and IRES/IL21.  P < 0.05 and  P < 0.01, as compared with IRES/GM-SCF-IL21.

Back to article page